Form 6-K CytoMed Therapeutics For: Jan 13
Tweet
Share
E-mail
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2026
Commission File Number: 001-41677
CytoMed Therapeutics Limited
(Exact name of registrant as specified in its charter)
1 Commonwealth Lane
#08-22
Singapore 149544
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On January 13, 2026, CytoMed Therapeutics Limited (the “Company”) issued a press release announcing its new year update and inviting shareholders to provide feedback on a proposal to enhance shareholders’ patient capital.
A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CytoMed Therapeutics Limited | ||
| By: | /s/ CHOO Chee Kong | |
| Name: | CHOO Chee Kong | |
| Date: January 13, 2026 | Title: | Director and Chairman |
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sportradar Investors Who Suffered Losses Urged to Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC as Securities Fraud Class Action Cites Compliance Misrepresentations and 22% Stock Decline
- Charlotte Tilbury awarded CBE in the King’s Birthday Honours 2026
- Gencor Releases Second Quarter Fiscal 2026 Results
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
